MA50280A - Procédés et compositions pour améliorer l'immunogénicité de tumeurs [ - Google Patents

Procédés et compositions pour améliorer l'immunogénicité de tumeurs [

Info

Publication number
MA50280A
MA50280A MA050280A MA50280A MA50280A MA 50280 A MA50280 A MA 50280A MA 050280 A MA050280 A MA 050280A MA 50280 A MA50280 A MA 50280A MA 50280 A MA50280 A MA 50280A
Authority
MA
Morocco
Prior art keywords
compositions
methods
tumor immunogenicity
improving tumor
tumor
Prior art date
Application number
MA050280A
Other languages
English (en)
Inventor
Alan Gordon Herbert
Original Assignee
Insideoutbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insideoutbio Inc filed Critical Insideoutbio Inc
Publication of MA50280A publication Critical patent/MA50280A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés et des compositions pour améliorer l'immunogénicité d'une tumeur d'intérêt par modulation/modification de l'expression de protéines du complément spécifiques et de récepteurs de protéine du complément associés à la suppression immunitaire d'une tumeur/cellule tumorale.
MA050280A 2017-09-11 2018-09-11 Procédés et compositions pour améliorer l'immunogénicité de tumeurs [ MA50280A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556836P 2017-09-11 2017-09-11
US201762582365P 2017-11-07 2017-11-07
US201862656495P 2018-04-12 2018-04-12

Publications (1)

Publication Number Publication Date
MA50280A true MA50280A (fr) 2020-07-22

Family

ID=63762991

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050280A MA50280A (fr) 2017-09-11 2018-09-11 Procédés et compositions pour améliorer l'immunogénicité de tumeurs [

Country Status (6)

Country Link
US (1) US20200262879A1 (fr)
EP (1) EP3682006A1 (fr)
JP (1) JP2020533414A (fr)
CN (1) CN111315885A (fr)
MA (1) MA50280A (fr)
WO (1) WO2019051443A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210403519A1 (en) * 2018-11-02 2021-12-30 Insideoutbio, Inc. Methods and compositions to induce or suppress immune responses through the use of membrane bound complement split products
CN109666693B (zh) * 2018-12-29 2022-08-16 北京市农林科学院 Mg132在碱基编辑系统编辑受体基因组中的应用
WO2021072031A1 (fr) * 2019-10-11 2021-04-15 Insideoutbio, Inc. Procédés et compositions pour la fabrication et l'utilisation d'agents thérapeutiques codés par de l'adn circulaire dans des troubles génétiques et d'autres maladies
CN114686481B (zh) * 2020-12-31 2023-08-15 北京键凯科技股份有限公司 一种抑制cfd表达的干扰rna及其制备方法和应用
KR20240010451A (ko) * 2021-03-11 2024-01-23 에멘도바이오 인코포레이티드 C3 세이프 하버 부위에서의 넉인 전략
GB202107586D0 (en) 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
EP4311574A1 (fr) * 2022-07-29 2024-01-31 Chung-Ang University Industry-Academic Cooperation Prévention et traitement de la dégénérescence maculaire liée à l'âge par suppression de l'expression de la cathepsine s
CN120590505B (zh) * 2025-06-06 2026-05-12 上海交通大学医学院附属新华医院 一种重组补体蛋白及在制备抗白血病药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
GB9424631D0 (en) 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
BR9708387A (pt) 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
US20030103984A1 (en) * 1998-05-04 2003-06-05 Heinz Kohler Fusion proteins of biologically active peptides and antibodies
US20150231227A1 (en) 2000-03-02 2015-08-20 Emory University Compositions and methods for generating an immune response
US7371387B2 (en) 2001-02-21 2008-05-13 Genitrix Llc Vaccine compositions and methods of modulating immune responses
AU2002336760A1 (en) 2001-09-26 2003-06-10 Mayo Foundation For Medical Education And Research Mutable vaccines
WO2009121065A2 (fr) 2008-03-28 2009-10-01 Apellis Ag Modulation et réplétion/amélioration du système complémentaire dans le traitement des traumatismes
DE102008049136B4 (de) * 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
GB0916997D0 (en) 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
WO2012021891A2 (fr) * 2010-08-13 2012-02-16 Tufts University Compositions, kits et méthodes de traitement de pathologies associées au complément
US9475853B2 (en) * 2012-01-19 2016-10-25 Albany Medical College Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
WO2014197885A2 (fr) * 2013-06-07 2014-12-11 Duke University Inhibiteurs du facteur h du complément
EP3092252B1 (fr) 2014-01-08 2019-09-18 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anticorps ciblant une protéine c3d du complément déposée sur une surface cellulaire, et utilisation de celui-ci
EP3230460B2 (fr) 2014-12-12 2023-11-29 James Zhu Procédés et compositions pour l'élimination sélective de cellules d'intérêt
WO2016145150A2 (fr) 2015-03-11 2016-09-15 The Broad Institute Inc. Traitement sélectif de cancer dépendant de prmt5
US20170020922A1 (en) 2015-07-16 2017-01-26 Batu Biologics Inc. Gene editing for immunological destruction of neoplasia
US10240145B2 (en) 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
AU2016375183B2 (en) 2015-12-23 2021-01-21 eleva GmbH Polypeptides for inhibiting complement activation

Also Published As

Publication number Publication date
US20200262879A1 (en) 2020-08-20
CN111315885A (zh) 2020-06-19
EP3682006A1 (fr) 2020-07-22
JP2020533414A (ja) 2020-11-19
WO2019051443A1 (fr) 2019-03-14

Similar Documents

Publication Publication Date Title
ZA202308519B (en) Anti-vegf protein compositions and methods for producing the same
CY1122494T1 (el) Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
ZA201708265B (en) Tigit-binding agents and uses thereof
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
EA201991912A1 (ru) Составы, содержащие pd-1-связывающие белки, и способы их получения
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
TR201910573T4 (tr) Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
ZA202003320B (en) Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
EA202191403A1 (ru) Композиция с высокой концентрацией белка
PE20200487A1 (es) Proteinas de union al antigeno anti-jagged1
EA202092694A1 (ru) Системы и способы количественного определения и модификации вязкости белков
EA201892085A1 (ru) Новые белки, полученные из альфа-1-микроглобулина, и их применение
JOP20210339A1 (ar) أجسام مضادة لـ angpt2